Cervical cancer screening, redesigned.
RapidCan is a CRISPR-based rapid diagnostic test for cervical cancer, designed to run a sample-to-result workflow outside a reference laboratory. Currently under CE marking review along the IVDR pathway.
What RapidCan does.
RapidCan detects cervical cancer markers using a CRISPR-based detection chemistry. The device runs a sample-to-result workflow in a single bench process — no specialised sample transport, no centralised reference laboratory.
The traditional pathway depends on a centralised lab: a sample is sent away, processed over days or weeks, and the result returned through a chain of intermediaries. RapidCan is designed to remove that dependency — to run the molecular signal where the sample is taken, by the same staff who took it.
RapidCan is currently under CE marking review along the IVDR pathway. Clinical studies are active. Verified performance characteristics will be communicated as those studies are published.
- Capability
Sample type
Cervical sample taken at point of care, no specialised sample transport required.
- Capability
Workflow
Sample-to-result in a single bench process, operated by trained clinical staff rather than laboratory technicians.
- Capability
Setting
Designed for use outside a centralised reference laboratory — clinics, community health programmes, and screening initiatives.
Designed for clinical use.
Healthcare providers
Clinicians and primary-care networks delivering cervical cancer screening to patients who need it — with or without local access to a reference laboratory.
Distributors
Partners placing diagnostic products into clinical and community settings across geographies, with the documentation each market expects.
Institutional buyers
Hospital systems, public health programmes, and screening initiatives sourcing tests at scale for population-level deployment.
Under CE marking review.
RapidCan is currently under CE marking review along the IVDR pathway. Clinical studies are active and ongoing. Verified performance characteristics will be communicated as those studies are published — we will not publish numbers we cannot defend in a peer-reviewed setting.
RapidCan is not yet CE certified and is not yet authorised for clinical use. Information on this page describes the product as currently in development and is not a representation that RapidCan is available for sale or clinical application.
Independent recognition for our work.
1st place — Hospiton Cancer Hackathon
Recognised for the early RapidCan concept against entries from clinical and engineering teams across Europe.
Invited to Cambridge University
Selected for an in-person research and translation programme at Cambridge to advance the diagnostic platform.
BSV Ventures Incubation
Shortlisted for BSV Ventures' #7 incubation programme — one of a small group of deep-tech startups selected from across Europe and the United States.
Partnership with Nacionalinis vėžio centras
Partnership with the National Cancer Center in Lithuania, supporting clinical translation and validation work.
Be first when RapidCan ships.
Preorder is registering interest, not purchasing. No payment is captured today — we’ll contact you when shipping begins and walk you through pricing, tiers, and the documentation your organisation needs at that stage.
Build with us.
Whether you’re evaluating RapidCan for a clinic, a distribution network, or a screening initiative, we’d like to hear from you.